Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 36

1.

Photodistribution of blue-gray hyperpigmentation after amiodarone treatment: molecular characterization of amiodarone in the skin.

Ammoury A, Michaud S, Paul C, Prost-Squarcioni C, Alvarez F, Lamant L, Launay F, Bazex J, Chouini-Lalanne N, Marguery MC.

Arch Dermatol. 2008 Jan;144(1):92-6. doi: 10.1001/archdermatol.2007.25.

PMID:
18209173
2.

[Skin adverse effects of amiodarone].

Zgazarová S, Jedlicková H, Vasků V.

Vnitr Lek. 2009 Oct;55(10):976-80. Review. Czech.

PMID:
19947243
3.

Reversibility of blue-gray cutaneous discoloration from amiodarone.

Blackshear JL, Randle HW.

Mayo Clin Proc. 1991 Jul;66(7):721-6. Review.

PMID:
2072759
4.

Diltiazem-induced photodistributed hyperpigmentation.

Boyer M, Katta R, Markus R.

Dermatol Online J. 2003 Dec;9(5):10. Review.

5.

Imipramine-induced hyperpigmentation: four cases and a review of the literature.

Ming ME, Bhawan J, Stefanato CM, McCalmont TH, Cohen LM.

J Am Acad Dermatol. 1999 Feb;40(2 Pt 1):159-66. Review.

PMID:
10025739
6.

Drug-induced skin pigmentation. Epidemiology, diagnosis and treatment.

Dereure O.

Am J Clin Dermatol. 2001;2(4):253-62. Review.

PMID:
11705252
7.

Diltiazem-associated photodistributed hyperpigmentation: report of two Japanese cases and published work review.

Kubo Y, Fukumoto D, Ishigami T, Hida Y, Arase S.

J Dermatol. 2010 Sep;37(9):807-11. doi: 10.1111/j.1346-8138.2010.00858.x. Review.

PMID:
20883365
8.

Extensive cutaneous hyperpigmentation caused by minocycline.

Pepine M, Flowers FP, Ramos-Caro FA.

J Am Acad Dermatol. 1993 Feb;28(2 Pt 2):292-5. Review.

PMID:
8436641
9.

[Ocular findings associated to the use of amiodarone].

Riihelä K, Mäntyjärvi M.

Duodecim. 1996;112(9):766-71. Review. Finnish. No abstract available.

PMID:
10592960
10.

Reduction in the appearance of facial hyperpigmentation by topical N-acetyl glucosamine.

Bissett DL, Robinson LR, Raleigh PS, Miyamoto K, Hakozaki T, Li J, Kelm GR.

J Cosmet Dermatol. 2007 Mar;6(1):20-6. Review.

PMID:
17348991
11.

[Thyroid and treatment with amiodarone diagnosis, therapy and clinical management].

Mikosch P.

Wien Med Wochenschr. 2008;158(1-2):29-35. doi: 10.1007/s10354-007-0475-x. Review. German.

PMID:
18286247
12.

[Non-thyroidal side effects of amiodarone].

Creplet J.

Rev Med Brux. 1996 Sep;17(4):198-202. Review. French.

PMID:
8927844
13.

Amiodarone and optic neuropathy: the heart of the matter.

Murphy MA, Murphy JF.

J Neuroophthalmol. 2005 Sep;25(3):232-6. Review.

PMID:
16148635
14.

Cutaneous adverse reactions of amiodarone.

Jaworski K, Walecka I, Rudnicka L, Gnatowski M, Kosior DA.

Med Sci Monit. 2014 Nov 21;20:2369-72. doi: 10.12659/MSM.890881. Review.

15.

Benzofuran derivatives and the thyroid.

Han TS, Williams GR, Vanderpump MP.

Clin Endocrinol (Oxf). 2009 Jan;70(1):2-13. doi: 10.1111/j.1365-2265.2008.03350.x. Epub 2008 Aug 22. Review.

PMID:
18727707
16.

[Amiodarone-induced pulmonary toxicity].

Heisel A, Berg M, Stopp M, Ukena D, Schieffer H.

Med Klin (Munich). 1997 Dec;92 Suppl 5:33-6. doi: 10.1007/BF03041977. Review. German.

PMID:
19479394
17.

Antiarrhythmic drugs for atrial fibrillation: focus on dronedarone.

Krishnamoorthy S, Lip GY.

Expert Rev Cardiovasc Ther. 2009 May;7(5):473-81. doi: 10.1586/erc.09.14. Review.

PMID:
19419255
18.

Dronedarone: a new antiarrhythmic agent for the treatment of atrial fibrillation.

Garcia D, Cheng-Lai A.

Cardiol Rev. 2009 Sep-Oct;17(5):230-4. doi: 10.1097/CRD.0b013e3181b15ab9. Review.

PMID:
19690474
19.

Dronedarone.

Patel C, Yan GX, Kowey PR.

Circulation. 2009 Aug 18;120(7):636-44. doi: 10.1161/CIRCULATIONAHA.109.858027. Review.

20.

Hyperpigmentation and melasma.

Rigopoulos D, Gregoriou S, Katsambas A.

J Cosmet Dermatol. 2007 Sep;6(3):195-202. Review.

PMID:
17760699

Supplemental Content

Support Center